• Profile
Close

Discontinuation rates of warfarin vs direct acting oral anticoagulants in US clinical practice: Results from ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

American Heart Journal May 06, 2020

Jackson LR, Kim S, Blanco R, et al. - Given that although oral anticoagulation represents a cornerstone of stroke prevention treatment in atrial fibrillation (AF), few investigations have assessed comparative discontinuation rates in clinical practice, so researchers determined discontinuation rates in patients receiving warfarin and direct oral anticoagulants (DOACs) in clinical practice. The ORBIT-AF II Registry was used, which incorporated 10,005 total AF patients with a CHA2DS2VASc score of ≥ 2 on warfarin or DOACs from 235 clinical practices across the US from February 13, 2013 and July 12, 2017. Findings revealed higher adjusted rates of discontinuation in DOAC-treated vs vitamin K anticoagulants-treated patients at 12-months in a community based AF cohort. Experts also noted increased absolute risk of all-cause mortality and cardiovascular death in relation to discontinuation of oral anticoagulation.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay